Skip to Main Content
Contribute Try STAT+ Today

The House Oversight Committee will hold two days of hearings this week with six drug industry CEOs. The hearings are the presumptive climax of an 18-month investigation first launched by the late Rep. Elijah Cummings in 2019.

The hearing could be the most perilous yet for drug makers, who have managed to avoid any major missteps at the multiple congressional drug pricing hearings that preceded this one. The committee’s probe was extensive: Staff reviewed more than a million pages of internal documents from drug companies. And while we don’t know yet what the committee plans to reveal during the hearings, which are scheduled for Wednesday and Thursday, many of the drugs at the center of the probe already have a long and sordid history when it comes to pricing.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.